Literature DB >> 26535988

Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis.

Jidong Hong1, Zhongxing Liao1, Yan Zhuang1, Lawrence B Levy1, Tommy Sheu1, John V Heymach2, Quynh-Nhu Nguyen1, Ting Xu1, Ritsuko Komaki1, Daniel R Gomez1.   

Abstract

PURPOSE: We analyzed overall and disease-free survival (OS and DFS) after definitive (chemo)radiation for stage III non-small cell lung cancer with 2 statistical methods: Kaplan-Meier (KM) analysis, with diagnosis as index date, and conditional survival (CS) analysis, with a variety of disease-free index dates, and determined whether prognostic factors varied based on the reference date.
MATERIALS AND METHODS: All 651 patients analyzed received definitive (chemo)radiotherapy for stage III non-small cell lung cancer in November 1998 to December 2010 at a single institution; all had Karnofsky performance status scores ≥60 and received ≥60 Gy. OS and DFS were first calculated with the KM method, and then CS was used to calculate 2 outcomes: OS conditioned on DFS time (OS|DFS) and DFS conditioned on DFS time (DFS|DFS). Factors predicting OS and DFS conditioned on 1-, 2-, and 3-year DFS were sought in univariate and multivariate analyses.
RESULTS: KM analysis produced 1-, 2-, and 3-year DFS rates of 48%, 30%, and 26%; OS rates were 64%, 41%, and 29%. By CS analysis, both OS|DFS and DFS|DFS showed an increase in 5-year OS after 6 months, and CS after 30 months approached 100%. On multivariate analyses, age and concurrent chemoradiation predicted OS|DFS; age, smoking history, tumor histology, disease stage, and radiation dose predicted DFS|DFS.
CONCLUSIONS: CS analysis showed that the probability of long-term survival increases sharply after 6 months with no evidence of disease; factors predicting survival differed based on the method and endpoint used.

Entities:  

Mesh:

Year:  2018        PMID: 26535988      PMCID: PMC4854821          DOI: 10.1097/COC.0000000000000235

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  15 in total

1.  Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.

Authors:  Skye C Mayo; Hari Nathan; John L Cameron; Kelly Olino; Barish H Edil; Joseph M Herman; Kenzo Hirose; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

2.  The international system for staging lung cancer.

Authors:  C F Mountain
Journal:  Semin Surg Oncol       Date:  2000-03

3.  Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume.

Authors:  Kiyoshi Basaki; Yoshinao Abe; Masahiko Aoki; Hidehiro Kondo; Yoshiomi Hatayama; Shigeyuki Nakaji
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-13       Impact factor: 7.038

4.  Conditional survival in gastric cancer: a SEER database analysis.

Authors:  Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

5.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Authors:  J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

Review 6.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

7.  Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

Authors:  Beth A Zamboni; Greg Yothers; Mehee Choi; Clifton D Fuller; James J Dignam; Peter C Raich; Charles R Thomas; Michael J O'Connell; Norman Wolmark; Samuel J Wang
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

8.  Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.

Authors:  M Werner-Wasik; C Scott; J D Cox; W T Sause; R W Byhardt; S Asbell; A Russell; R Komaki; J S Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

9.  Conditional relative survival in head and neck squamous cell carcinoma: Permanent excess mortality risk for long-term survivors.

Authors:  Marc P van der Schroeff; Saskia A M van de Schans; Jay F Piccirillo; Ton P M Langeveld; Robert J Baatenburg de Jong; Maryska L G Janssen-Heijnen
Journal:  Head Neck       Date:  2010-12       Impact factor: 3.147

10.  Ethnic disparities in conditional survival of patients with non-small cell lung cancer.

Authors:  Samuel J Wang; C David Fuller; Charles R Thomas
Journal:  J Thorac Oncol       Date:  2007-03       Impact factor: 15.609

View more
  1 in total

1.  The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.

Authors:  Yuichiro Takeda; Yusaku Kusaba; Yoko Tsukita; Yukari Uemura; Eisaku Miyauchi; Takaya Yamamoto; Hiroshi Mayahara; Akito Hata; Hidetsugu Nakayama; Satoshi Tanaka; Junji Uchida; Kazuhiro Usui; Tatsuya Toyoda; Motohiro Tamiya; Masahiro Morimoto; Yuko Oya; Takeshi Kodaira; Keiichi Jingu; Hisatoshi Sugiura
Journal:  Clin Transl Radiat Oncol       Date:  2022-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.